Thomas Chang | Academic Influence

Thomas Chang's AcademicInfluence.com Rankings

Thomas Chang

Philosophy

#4523

World Rank

#7072

Historical Rank

Logic

#2061

World Rank

#2960

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Thomas Chang's Degrees

PhD Medical Science University of British Columbia

Why Is Thomas Chang Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Thomas Ming Swi Chang, is a Chinese-born Canadian inventor, physician, and physiologist. While an undergraduate at McGill University in 1957, Chang invented the world's first artificial cell. Working with improvised materials like perfume atomizers inside his dorm room turned laboratory, Chang managed to create a permeable plastic sack that would effectively carry haemoglobin almost as effectively as a natural blood cell. He went on to complete his B.Sc. , M.D., C.M. , and Ph.D degrees at McGill. Chang's career continued as founder and Director of the Artificial Cells and Organs Research Centre and Professor of Physiology, Medicine & Biomedical Engineering in the Faculty of Medicine at McGill University.

(See a Problem?)

Thomas Chang's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cell encapsulation: Promise and progress (2003) (557)
History, challenges and perspectives of cell microencapsulation. (2004) (346)
Semipermeable aqueous microcapsules. I. Preparation and properties. (1966) (326)
Therapeutic applications of polymeric artificial cells (2005) (282)
Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties (1998) (200)
A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. (1999) (180)
Biomedical Applications of Immobilized Enzymes and Proteins (1977) (173)
Stabilisation of enzymes by microencapsulation with a concentrated protein solution or by microencapsulation followed by cross-linking with glutaraldehyde. (1971) (161)
Blood Substitutes: Principles, Methods, Products, and Clinical Trials (1998) (147)
The in vivo Effects of Semipermeable Microcapsules containing L-Asparaginase on 6C3HED Lymphosarcoma (1971) (136)
Removal of endogenous and exogenous toxins by a microencapsulated absorbent. (1969) (135)
Therapeutic uses of microencapsulated genetically engineered cells. (1998) (105)
Procedures for microencapsulation of enzymes, cells and genetically engineered microorganisms (2001) (94)
Future prospects for artificial blood. (1999) (93)
The development and first clinical use of semipermeable microcapsules (artificial cells) as a compact artificial kidney. (2000) (87)
CROSS-LINKED POLYHEMOGLOBIN-SUPEROXIDE DISMUTASE-CATALASE SUPPLIES OXYGEN WITHOUT CAUSING BLOOD BRAIN BARRIER DISRUPTION OR BRAIN EDEMA IN A RAT MODEL OF TRANSIENT GLOBAL BRAIN ISCHEMIA-REPERFUSION (2002) (87)
Hepatocytes immobilised by microencapsulation in artificial cells: effects on hyperbilirubinemia in Gunn rats. (1989) (87)
RED BLOOD CELL SUBSTITUTES* (1998) (84)
The viability and regeneration of artificial cell microencapsulated rat hepatocyte xenograft transplants in mice. (1988) (72)
Analysis of Polyethylene‐glycol‐polylactide Nano‐Dimension Artificial Red Blood Cells in Maintaining Systemic Hemoglobin Levels and Prevention of Methemoglobin Formation (2003) (72)
Submicron polymer membrane hemoglobin nanocapsules as potential blood substitutes: preparation and characterization. (1996) (71)
Artificial cells with emphasis on bioencapsulation in biotechnology. (1995) (70)
Hemoglobin-based red blood cell substitutes. (2004) (69)
Phenylalanine ammonia-lyase immobilized in microcapsules for the depletion of phenylalanine in plasma in phenylketonuric rat model. (1986) (68)
Artificial liver: the effect of ACAC microencapsulated charcoal hemoperfusion on fulminant hepatic failure. (2008) (67)
Microcapsule artificial kidney: treatment of patients with acute drug intoxication. (1973) (64)
Transdifferentiation of bioencapsulated bone marrow cells into hepatocyte‐like cells in the 90% hepatectomized rat model (2006) (63)
Platelet-surface interaction: effect of albumin coating or heparin complexing on thrombogenic surfaces. (1974) (62)
Recent and future developments in modified hemoglobin and microencapsulated hemoglobin as red blood cell substitutes. (1997) (62)
Artificial Kidney, Artificial Liver, and Artificial Cells (1978) (62)
Blood substitutes based on nanobiotechnology. (2006) (61)
Comparison of the enzyme kinetics and immunological properties of catalase immobilized by microencapsulation and catalase in free solution for enzyme replacement (1974) (61)
A novel two step procedure for immobilizing living cells in microcapsules for improving xenograft survival. (1991) (59)
Artificial Cells: Biotechnology, Nanomedicine, Regenerative Medicine, Blood Substitutes, Bioencapsulation, and Cell/Stem Cell Therapy (2007) (57)
Structure and dynamics of N,N-diethyl-N-methylammonium triflate ionic liquid, neat and with water, from molecular dynamics simulations. (2010) (56)
Brain edema and the blood brain barrier in galactosamine-induced fulminant hepatic failure rats. An animal model for evaluation of liver support systems. (1990) (56)
Numerical investigation of non-Newtonian microcirculatory blood flow in hepatic lobule. (2006) (54)
Phenylalanine ammonia‐lyase immobilized in semipermeable microcapsules for enzyme replacement in phenylketonuria (1985) (53)
Blood replacement with nanobiotechnologically engineered hemoglobin and hemoglobin nanocapsules. (2010) (52)
From artificial red blood cells, oxygen carriers, and oxygen therapeutics to artificial cells, nanomedicine, and beyond (2012) (52)
Clinical evaluation of chronic, intermittent, and short term hemoperfusions in patients with chronic renal failure using semipermeable microcapsules (artificial cells) formed from membrane-coated activated charcoal. (1971) (52)
Crosslinked hemoglobin-superoxide dismutase-catalase scavenges free radicals in a rat model of intestinal ischemia-reperfusion injury. (1997) (51)
In-vivo degradation of poly(lactic acid) of different molecular weights. (1985) (49)
Kinetics of thermally induced solid state polycondensation of poly(ethylene terephthalate) (1970) (46)
A new theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in phenylketonuria. (1995) (45)
The recycling of NAD+ (free and immobilized) within semipermeable aqueous microcapsules containing a multi-enzyme system. (1976) (45)
The microencapsulation of cells within alginate poly-L-lysine microcapsules prepared with the standard single step drop technique: histologically identified membrane imperfections and the associated graft rejection. (1991) (44)
Semipermeable aqueous microcapsules. IV. Nonthrombogenic microcapsules with heparin-complexed membranes. (1967) (44)
Formation of amino acid from urea and ammonia by sequential enzyme reaction using a microencapsulated multi-enzyme system. (1977) (44)
Submicron biodegradable polymer membrane hemoglobin nanocapsules as potential blood substitutes: a preliminary report. (1994) (44)
Albumin-collodion activated charcoal hemoperfusion in the treatment of severe theophylline intoxication in a 3-year-old patient. (1980) (43)
Semipermeable aqueous microscapsules. Artificial cells. V. Permeability characteristics. (1968) (42)
Polyhemoglobin-superoxide Dismutase-catalase-carbonic Anhydrase: A Novel Biotechnology-based Blood Substitute that Transports both Oxygen and Carbon Dioxide and also Acts as an Antioxidant (2011) (42)
Epnzymatric recycling of coenzymes by a multi-enzyme system immobilized within semipermeable collodion microcapsules. (1975) (41)
Polydisperse dextran as a diffusing test solute to study the membrane permeability of alginate polylysine microcapsules. (1993) (41)
Absence of hemoprotein-associated free radical events following oxidant challenge of crosslinked hemoglobin-superoxide dismutase catalase. (1998) (41)
Pharmaceutical and therapeutic applications of artificial cells including microencapsulation. (1998) (41)
Blood substitutes based on modified hemoglobin prepared by encapsulation or crosslinking: an overview. (1992) (40)
A novel nanobiotherapeutic poly-[hemoglobin-superoxide dismutase-catalase-carbonic anhydrase] with no cardiac toxicity for the resuscitation of a rat model with 90 minutes of sustained severe hemorrhagic shock with loss of 2/3 blood volume (2014) (40)
Hybrid artificial cells: microencapsulation of living cells. (1992) (40)
Preparation and in vitro characteristics of a blood substitute based on pyridoxylated polyhemoglobin. (1984) (39)
Nanobiotechnology for hemoglobin-based blood substitutes. (2009) (39)
Free and Microencapsulated Lactobacillus and Effects of Metabolic Induction on Urea Removal (2003) (38)
Plasma perfused over immobilized protein A for breast cancer. (1982) (38)
Effects of hemoperfusion rate and time of initiation of ACAC charcoal hemoperfusion on the survival of fulminant hepatic failure rats. (1978) (38)
Recycling of NAD(P) by multienzyme systems immobilized by microencapsulation in artificial cells. (1987) (37)
Clincial performance characteristics of a new combined system for simulatenous hemoperfusion-hemodialysis-ultrafiltration in series. (1975) (36)
Blood substitutes and oxygen carriers (1993) (35)
Two future generations of blood substitutes based on polyhemoglobin-SOD-catalase and nanoencapsulation. (2000) (35)
Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. (1976) (34)
Biochemical, hematological and histological changes in a fulminant hepatic failure rat model for artificial liver assessment. (1979) (34)
Pyridoxylated polyhemoglobin as a red cell substitute for resuscitation of lethal hemorrhagic shock in conscious rats. (1985) (34)
[15] Artificial cells containing multienzyme systems (1985) (33)
Evaluation of Two Protocols of Uremic Rat Model: Partial Nephrectomy and Infarction (2003) (33)
Medical applications of immobilized proteins, enzymes, and cells. (1988) (32)
Artificial cells for cell and organ replacements. (2004) (32)
Applications of artificial cells in medicine and biotechnology. (1987) (31)
Artificial liver support based on artificial cells with emphasis on encapsulated hepatocytes. (2008) (31)
INCREASED VIABILITY OF TRANSPLANTED HEPATOCYTES WHEN HEPATOCYTES ARE CO-ENCAPSULATED WITH BONE MARROW STEM CELLS USING A NOVEL METHOD (2002) (31)
Semipermeable aqueous microcapsules ("artificial cells"): with emphasis on experiments in an extracorporeal shunt system. (1966) (31)
Effect of a single replacement of one of Ringer lactate, hypertonic saline/dextran, 7g% albumin, stroma-free hemoglobin, o-raffinose polyhemoglobin or whole blood on the long term survival of unanesthetized rats with lethal hemorrhagic shock after 67% acute blood loss. (1992) (31)
Immobilization of alcohol dehydrogenase, malic dehydrogenase and dextran—NAD+ within nylon-polyethyleneimine microcapsules: preparation and cofactor recycling (1981) (30)
ARTIFICIAL CELL evolves into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, replicating synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent haemoperfusion/pla (2019) (30)
Artificial cell microencapsulated stem cells in regenerative medicine, tissue engineering and cell therapy. (2010) (29)
Artificial cells in medicine and biotechnology (1984) (29)
Comparison of polymerically stabilized PEG-grafted liposomes and physically adsorbed carboxymethylchitin and carboxymethyl/glycolchitin liposomes for biological applications. (1998) (29)
Artificial cells microencapsulated multienzyme system for converting urea and ammonia to amino acid using alpha-ketoglutarate and glucose as substrate. (1978) (29)
Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report. (1995) (29)
Polyhemoglobin-Fibrinogen: A Novel Oxygen Carrier with Platelet-Like Properties in a Hemodiluted Setting (2007) (28)
Enhanced albumin binding to polypropylene beads via anhydrous ammonia gaseous plasma. (1986) (28)
Immobilization of multienzymes and cofactors within lipid-polyamide membrane microcapsules for the multistep conversion of lipophilic and lipophobic substrates (1982) (28)
Comparisons of six artificial liver support regimes in fulminant hepatic coma rats. (1980) (28)
Serum middle molecule levels in uremia during long term intermittent hemoperfusions with the acac (coated charcoal) microcapsule artificial kidney. (1974) (28)
Nylon polyethyleneimine microcapsules for immobilizing multienzymes with soluble dextran-NAD+ for the continuous recycling of the microencapsulated dextran-NAD+. (1978) (27)
Immobilization of enzymes on polypropylene bead surfaces by anhydrous ammonia gaseous plasma technique. (1988) (27)
Production of essential L‐branched‐chain amino acids in bioreactors containing artificial cells immobilized multienzyme systems and dextran–NAD+ (1990) (27)
Control release of prostaglandin E2 from polylactic acid microcapsules, microparticles and modified microparticles. (1988) (26)
Response to intermittent extracorporeal perfusion through shunts containing semipermeable microcapsules. (1968) (26)
In vitro study of multicellular hepatocyte spheroids formed in microcapsules. (2008) (25)
Artificial cells with emphasis on cell encapsulation of genetically engineered cells. (1998) (25)
Polyhemoglobin with Different Percentage of Tetrameric Hemoglobin and Effects on Vasoactivity and Electrocardiogram (2006) (24)
Oxygen carriers. (2002) (24)
BIOPHYSICAL PROPERTIES* (2002) (24)
Blood compatible coating of synthetic immunoadsorbents. (1980) (24)
Effects of glucose dehydrogenase in converting urea and ammonia into amino acid using artificial cells. (1979) (23)
Evolution of Artificial Cells Using Nanobiotechnology of Hemoglobin Based RBC Blood Substitute as an Example (2006) (23)
Cross-linked hemoglobin-superoxide dismutase-catalase scavenges oxygen-derived free radicals and prevents methemoglobin formation and iron release. (1993) (23)
Effects of oral administration of artificial cells immobilized phenylalanine ammonia-lyase on intestinal amino acids of phenylketonuric rats. (1989) (23)
Artificial Cells and Bioencapsulation in Bioartificial Organs a (1997) (22)
Effects of mass transfer and reaction kinetics on serum cholesterol depletion rates of free and immobilizedPseudomonas pictorwn (1991) (22)
Growth and survival of renal failure rats that received oral microencapsulated genetically engineered E. coli DH5 cells for urea removal. (1998) (22)
Conversion of α‐ketoglutarate into L‐glutamic acid with urea as ammonium source using multienzyme systems and dextran‐NAD+ immobilized by microencapsulation within artificial cells in a bioreactor (1988) (22)
Artificial cell-microencapsulated phenylalanine ammonia-lyase (1984) (21)
Artificial cells for bioencapsulation of cells and genetically engineered E. coli. For cell therapy, gene therapy, and removal of urea and ammonia. (1997) (21)
Bioencapsulated hepatocytes for experimental liver support. (2001) (21)
Extraction of Erythrocyte Enzymes for the Preparation of Polyhemoglobin-catalase-superoxide Dismutase (2009) (21)
Diacytosis of 125I-asialoorosomucoid by rat hepatocytes. A non-lysosomal pathway insensitive to inhibition by inhibitors of ligand degradation. (1984) (21)
Artificial Cells Microencapsulated Genetically Engineered E. Coli DH 5 Cells for the Lowering of Plasma Creatinine In-Vitro and In-Vivo (2000) (20)
Immunological effects of hemoglobin, encapsulated hemoglobin, polyhemoglobin and conjugated hemoglobin using different immunization schedules. (1992) (20)
Artificial cells, encapsulation, and immobilization. (1999) (20)
Artificial Cell Bioencapsulation in Macro, Micro, Nano, and Molecular Dimensions: Keynote Lecture (2004) (20)
Hydrodynamics and urea hydrolysis in a microencapsulated urease, fluidized bed reactor (1986) (20)
Pyridoxylated-polyhemoglobin solution: a low viscosity oxygen-delivering blood replacement fluid with normal oncotic pressure and long-term storage feasibility. (1988) (19)
Microencapsulation of enzymes and biologicals. (1976) (19)
Long-term Effects on the Histology and Function of Livers and Spleens in Rats after 33% Toploading of PEG-PLA-nano Artificial Red Blood Cells (2008) (19)
Preparation and characterisation of xanthine oxidase immobilised by microencapsulation in artificial cells for the removal of hypoxanthine. (1989) (19)
Artificial Cell Biotechnology for Medical Applications (2000) (19)
Effects of hepatic stimulatory factor released from free or microencapsulated hepatocytes on galactosamine induced fulminant hepatic failure animal model. (1991) (18)
Application of Materials in Medicine, Biology, and Artificial Organs (1996) (18)
Xenotransplantation of microencapsulated canine islets into diabetic rats. (1994) (18)
New Method for Preparing More Stable Microcapsules for the Entrapment of Genetically Engineered Cells (2005) (18)
Nanobiotechnological Nanocapsules Containing Polyhemoglobin-Tyrosinase: Effects on Murine B16F10 Melanoma Cell Proliferation and Attachment (2012) (18)
[Artificial cells in medicine and biotechnology]. (1984) (18)
Clinical evaluation of the clearance profiles of a portable, compact, dialysate-free system incorporating microencapsulated charcoal hemoperfusion for blood purification with ultrafiltration for fluid removal. (1977) (17)
New Approaches Using Immobilized Enzymes for the Removal of Urea and Ammonia (1980) (17)
Artificial cell microcapsules containing genetically engineered E. coli DH5 cells for in-vitro lowering of plasma potassium, phosphate, magnesium, sodium, chloride, uric acid, cholesterol, and creatinine: a preliminary report. (1999) (17)
Towards an artificial cornea: surface modifications of optically clear, oxygen permeable soft contact lens materials by ammonia plasma modification technique for the enhanced attachment and growth of corneal epithelial cells. (1990) (17)
Preliminary Study on Intrasplenic Implantation of Artificial Cell Bioencapsulated Stem Cells to Increase the Survival of 90% Hepatectomized Rats (2009) (17)
GENERAL CONSIDERATION * (2002) (17)
Long-term reduced time hemoperfusion-hemodialysis compared to standard dialysis: a preliminary crossover analysis. (1985) (17)
Immunological and systemic effects of transfusions in rats using pyridoxylated hemoglobin and polyhemoglobin from homologous and heterogeneous sources. (1988) (17)
Red blood cell substitutes: microencapsulated hemoglobin and cross-linked hemoglobin including pyridoxylated polyhemoglobin & conjugated hemoglobin. (1988) (17)
Effects of prostaglandin E2 on brain edema and liver histopathology in a galactosamine-induced fulminant hepatic failure rat model. (1987) (17)
Encapsulation of Enzymes, Cell Contents, Cells, Vaccines, Antigens, Antiserum, Cofactors, Hormones, and Proteins (1977) (17)
50th anniversary of artificial cells: their role in biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation, cell/stem cell therapy and nanorobotics. (2007) (16)
Superoxide dismutase and catalase cross-linked to polyhemoglobin reduces methemoglobin formation in vitro. (1995) (16)
Novel Nanodimension artificial red blood cells that act as O2 and CO2 carrier with enhanced antioxidant activity: PLA-PEG nanoencapsulated PolySFHb-superoxide dismutase-catalase-carbonic anhydrase (2013) (16)
Plasma/intestinal concentration patterns suggestive of entero-portal recirculation of amino acids: effects of oral administration of asparaginase, glutaminase and tyrosinase immobilized by microencapsulation in artificial cells. (1988) (16)
Effects of homologous and heterologous stroma-free hemoglobin and polyhemoglobin on complement activation, leucocytes and platelets. (1990) (16)
Assessment of blood substitutes: II. In-vitro complement activation of human plasma and blood for safety studies in research, development, industrial production and preclinical analysis. (1994) (16)
A screening test for modified hemoglobin blood substitutes before clinical use: based on C3a complement activation in human plasma. (1990) (15)
Reduction of hydroxyl radical generation in a rat hindlimb model of ischemia-reperfusion injury using crosslinked hemoglobin-superoxide dismutase-catalase. (1997) (15)
Study of microencapsulated urease in a continuous feed, stirred tank reactor (1984) (15)
Middle molecules in hepatic coma and uremia. (1981) (15)
Bioencapsulation in biotechnology. (1993) (15)
Nonthrombogenic surface by radiation grafting of heparin: preparation, in-vitro and in-vivo studies. (1974) (15)
Effects of PEG-PLA-nano Artificial Cells Containing Hemoglobin on Kidney Function and Renal Histology in Rats (2008) (15)
Recycling of NAD+ crosslinked to albumin or hemoglobin immobilized with multienzyme systems in artificial cells (1987) (15)
Present Status of Modified Hemoglobin as Blood Substitutes and Oral Therapy for End Stage Renal Failure Using Artificial Cells Containing Genetically Engineered Cells (2001) (14)
Intrasplenic Transplantation of Bioencapsulated Mesenchymal Stem Cells Improves the Recovery Rates of 90% Partial Hepatectomized Rats (2012) (14)
Immune Safety Evaluation of Polymerized Porcine Hemoglobin (pPolyHb): A Potential Red Blood Cell Substitute (2011) (14)
Microencapsulated genetically engineered E. coli DH5 cells for plasma urea and ammonia removal based on: 1. Column bioreactor and 2. Oral administration in uremic rats. (1996) (14)
Hemoperfusion, Exchange Transfusion, Cross Circulation, Liver Perfusion, Hormones and Immobilized Enzymes (1981) (14)
Pyridoxalated heterogenous and homologous polyhemoglobin and hemoglobin: systemic effects of replacement transfusion in rats previously received immunizing doses. (1987) (14)
Immobilization of P. pictorum in open pore agar, alginate and polylysine-alginate microcapsules for serum cholesterol depletion. (1989) (14)
PEG-PLA Nanocapsules Containing a Nanobiotechnological Complex of Polyhemoglobin-Tyrosinase for the Depletion of Tyrosine in Melanoma: Preparation and In Vitro Characterisation. (2012) (14)
Preparation and surface characterization of carboxymethylchitin-incorporated submicron bilayer-lipid membrane artificial cells (liposomes) encapsulating hemoglobin. (1991) (14)
The potential of a microencapsulated urease-zeolite oral sorbent for the removal of urea in uremia. (1991) (14)
The Immunological Properties of Stroma-free Polyhemolysate Containing Catalase and Superoxide Dismutase Activities Prepared by Polymerized Bovine Stroma-free Hemolysate (2010) (14)
Protective Effects of Microencapsulation (Coating) on Platelet Depletion and Particulate Embolism in the Clinical Applications of Charcoal Haemoperfusion (1977) (14)
Lowering of elevated tissue PCO2 in a hemorrhagic shock rat model after reinfusion of a novel nanobiotechnological polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase that is an oxygen and a carbon dioxide carrier with enhanced antioxidant properties (2013) (14)
Coencapsulation of hepatocytes and bone marrow cells: in vitro and in vivo studies. (2006) (14)
Immobilization and kinetics of lactate dehydrogenase at a rotating nylon disk (1988) (13)
Kinetic analysis of UDP-glucuronosyltransferase in bilirubin conjugation by encapsulated hepatocytes for transplantation into Gunn rats. (1995) (13)
Red blood cell replacement, or nanobiotherapeutics with enhanced red blood cell functions? (2015) (13)
Kinetic studies of hepatocyte UDP-glucuronosyltransferase: evidence of an allosteric enzyme. (1999) (13)
Modified hemoglobin as red blood cell substitutes. (1987) (13)
Intermittent vascular access for extracorporeal circulation in conscious rats: a new technique. (1982) (13)
Selected topics in nanomedicine (2013) (13)
Conversion of urea or ammonia into essential amino acids (L-leucine, L-valine, and L-isoleucine) using multienzyme systems and NADH-dextran immobilised in artificial cells. (1987) (13)
Preliminary report on effects of prostaglandin E2 on brain edema in fulminant hepatic failure rats. (1985) (13)
Modified hemoglobin blood substitutes: present status and future perspectives. (1998) (13)
Pharmacodynamic Study of Polymerized Porcine Hemoglobin (pPolyHb) in a Rat Model of Exchange Transfusion (2011) (13)
Genetically engineered E. coli cells containing K. aerogenes gene, microencapsulated in artificial cells for urea and ammonia removal. (1993) (13)
Extraction of superoxide dismutase, catalase, and carbonic anhydrase from stroma-free red blood cell hemolysate for the preparation of the nanobiotechnological complex of polyhemoglobin–superoxide dismutase–catalase–carbonic anhydrase (2015) (13)
Hemoperfusion, Plasmaperfusion and Other Clinical Uses of General, Biospecific, Immuno and Leucocyte Adsorbents (2017) (13)
"Attempts to find a method to prepare artificial hemoglobin corpuscles". (1988) (12)
Animal Remnant Kidney Model of Chronic Renal Failure Revisited (2003) (12)
Phase one clinical trial of a new composite artificial kidney: a single unit combining dialysis with hemoperfusion. (1982) (12)
Is There a Need for Blood Substitutes in the New Millennium and What Should we Expect in the Way of Safety and efficacy? (2000) (12)
Release of hepatic stimulatory substance from cultures of free and microencapsulated hepatocytes: preliminary report. (1988) (12)
Free and microencapsulated Erwinia herbicola for the production of tyrosine. (1993) (11)
Purification and characterization of liposomes encapsulating hemoglobin as potential blood substitutes. (1992) (11)
Hepatic uptake of asialoglycoprotein is different among mammalian species due to different receptor distribution. (1988) (11)
Artificial cells in immobilization biotechnology. (1992) (11)
Propentdyopent: the scaffold of a heme metabolite as an electron reservoir in transition metal complexes. (2016) (11)
Bilirubin removal by the pseudoperoxidase activity of free and immobilized hemoglobin and hemoglobin co-immobilized with glucose oxidase. (1989) (11)
A finite element study of the blood flow in total cavopulmonary connection (1999) (11)
Preparation of polylactic acid microcapsules containing ciprofloxacin. (1998) (11)
Biodegradable polylactic acid nanocapsules containing ciprofloxacin: preparation and characterization. (1999) (11)
A new red blood cell substitute. (2004) (11)
Artificial Cell Immobilized Multienzyme Systems and Cofactors (1982) (11)
Microencapsulated charcoal hemoperfusion: a possible therapeutic adjunct in digoxin toxicity. (1977) (10)
The use of modified hemoglobin as an oxygen carrying blood substitute. (1989) (10)
Effect of membrane thickness of collodion coated activated charcoal on adsorption of small and middle molecules. (1987) (10)
Growth kinetics of genetically engineered E. coli DH 5 cells in artificial cell APA membrane microcapsules: preliminary report. (1999) (10)
Temperature stability of Poly-[hemoglobin-superoxide dismutase-catalase-carbonic anhydrase] in the form of a solution or in the lyophilized form during storage at −80 °C, 4 °C, 25 °C and 37 °C or pasteurization at 70 °C (2016) (10)
Nanobiotechnological modification of hemoglobin and enzymes from this laboratory. (2008) (10)
Hepatoprotective effects of Poly-[hemoglobin-superoxide dismutase-catalase-carbonic anhydrase] on alcohol-damaged primary rat hepatocyte culture in vitro (2017) (10)
Effects of pyridoxalated polyhemoglobin and stroma-free hemoglobin on ADP-induced platelet aggregation. (1989) (10)
Adsorption of chitin derivatives onto liposomes: optimization of adsorption conditions. (1998) (10)
Assessment of blood substitutes: I. Efficacy studies in anesthetized and conscious rats with loss of 1/3, 1/2 and 2/3 blood volume. (1994) (10)
Physicochemical characteristics of hepatic stimulatory factor prepared from cell free supernatant of hepatocyte cultures. (1991) (10)
A 1978 perspective of hemoperfusion. (2008) (9)
Use of solubility parameters for the preparation of hemodialysis membrances (1975) (9)
Use of finger-prick human blood samples as a more convenient way for in-vitro screening of modified hemoglobin blood substitutes for complement activation: a preliminary report. (1993) (9)
The anaerobic reaction of bovine hemoglobin with divinyl sulfone: structural changes and functional consequences. (1993) (9)
Microcapsule Artificial Kidney in Replacement of Renal Function: With Emphasis on Adsorbent Hemoperfusion (1979) (9)
Methods for the therapeutic applications of immobilized enzymes. (1976) (9)
Biodegradable Nanocapsules Containing A Nanobiotechnological Complex for the In-vitro Suppression of A Melanoma Cell Line B16F10 (2016) (9)
Artificial Cells for Replacement of Metabolic Organ Functions (2003) (8)
Effects of Local Applications of Microencapsulated Catalase on the Response of Oral Lesions to Hydrogen Peroxide in Acatalasemia (1972) (8)
Long term safety and immunological effects of a nanobiotherapeutic, bovine poly-[hemoglobin-catalase-superoxide dismutase-carbonic anhydrase], after four weekly 5% blood volume top-loading followed by a challenge of 30% exchange transfusion (2018) (8)
Coated charcoal haemoperfusion. (1984) (8)
Artificial Cells as Bioreactive Biomaterials (1988) (8)
Design of a fluidized bed reactor for microencapsulated urease (1984) (8)
Sustained Drug Release Characteristics of Biodegradable Composite Poly(d,l)Lactic Acidpoly(I)Lactic Acid Microcapsules Containing Ciprofloxacin (2000) (8)
Microencapsulated Multi-Enzyme Systems as Vehicles for the Cyclic Regeneration of Free and Immobilized Coenzymes (1978) (8)
Blood substitutes based on modified hemoglobin and fluorochemicals. (1987) (8)
Selection and microencapsulation of an “NADH-oxidizing” bacterium and its use for NAD regeneration (1984) (8)
Rationale and Strategies for the Therapeutic Applications of Immobilized Enzymes (1977) (8)
A Comparison of Semipermeable Microcapsules and Standard Dialysers for Use in Separation (1974) (8)
Effects of polylactic acid microcapsules containing prostaglandin E2 on the survival rates of grade II coma galactosamine induced fulminant hepatic failure rats. (1987) (7)
The role of artificial cells in cell and organ transplantation in regenerative medicine. (2005) (7)
Effects of long-term oral administration of polymeric microcapsules containing tyrosinase on maintaining decreased systemic tyrosine levels in rats. (2004) (7)
The effects of homologous cross-circulation and in situ liver perfusion on fulminant hepatic failure rats. (1980) (7)
Dual effects include antioxidant and pro-oxidation of ascorbic acid on the redox properties of bovine hemoglobin (2018) (7)
Translational feasibility of soluble nanobiotherapeutics with enhanced red blood cell functions (2017) (7)
Drug delivery systems in biotechnology. (1988) (7)
In vivo assessment of pyridoxylated crosslinked polyhemoglobin as an artificial red cell substitute in rats. (1983) (7)
IN VITRO ENZYME KINETICS OF MICROENCAPSULATED TYROSINASE (2002) (7)
Endotoxin removed from hemoglobin solution using polymyxin-B immobilized fibre (PMX-F) followed by a new turbidometric endotoxin assay. (1992) (7)
Effects of Combined Oral Administration and Intravenous Injection on Maintaining Decreased Systemic Tyrosine Levels in Rats (2004) (7)
Bovine hemoglobin anaerobically reacted with divinyl sulfone: a potential source for hypothermic oxygen carriers. (1992) (7)
The effects of hemoperfusion using coated charcoal or tyrosinase artificial cells on middle molecules and tyrosine in brain and serum of hepatic coma rats. (1982) (7)
Microencapsulation and Artificial Cells (1984) (7)
Artificial cells: 35 years. (2008) (7)
Cross-linked hemoglobins being well into clinical trials, increasing research efforts are now on a second generation red blood cell substitute based on encapsulated hemoglobin. (1995) (7)
Toxicity of liposomes containing low mol% of dienoyl phosphocholine to blood: use of carboxymethyl chitin to reduce toxicity. (1994) (7)
Liver support/transplants and artificial organs. (1983) (6)
Artificial red blood cells. (1980) (6)
Experimental Therapy Using Semipermeable Microcapsules Containing Enzymes and Other Biologically Active Material (1977) (6)
l-Asparaginase as a Model for Enzyme Therapy of Substrate-Dependent Tumors (1977) (6)
ACAC (albumin-collodion coated activated charcoal) hemoperfusion: in-vitro removal and clearance of theophylline. (1980) (6)
Enhanced oxidation of bilirubin by an immobilized tri-enzyme system of glucose oxidase, bilirubin oxidase and horseradish peroxidase. (1989) (6)
In vitro and clinical studies of the removal of cortisol, thyroxine, insulin, and thyroid-stimulating hormone by coated charcoal haemoperfusion. (1984) (6)
Chronotropic Effect of Stroma-Free Hemoglobin and Polyhemoglobin on Cultured Myocardiocytes Derived from Newborn Rats (1988) (6)
Galactose Conversion Using a Microcapsule Immobilized Multienzyme Cofactor Recycling System (1978) (6)
Artificial Cells for Artificial Kidney, Artificial Liver and Detoxification (1978) (6)
Chronotropic effects of in vitro perfusion with albumin, stroma-free hemoglobin, and polyhemoglobin solutions. (1990) (6)
Polyhemoglobin–Tyrosinase, an Oxygen Carrier with Murine B16F10 Melanoma Suppression Properties: A Preliminary Report (2004) (5)
Circular dichroism study of membrane dynamics focused on effect of monosialogangliosides. (1988) (5)
Assessments of Two Rat Models of Fulminant Hepatic Failure for Testing Artificial Liver Devices (1978) (5)
Long-term clinical assessment of combined ACAC hemoperfusion-ultrafiltration in uremia. (1979) (5)
Analysis of a microencapsulated-urease fluidized-bed reactor under steady and transient state operating conditions (1986) (5)
Artificial cell-microencapsulated phenylalanine ammonia-lyase. (1984) (5)
Nanobiotherapeutic Based Blood Substitutes (2021) (5)
Poly(vinylidene fluoride)- or poly(vinylidene chloride/vinyl chloride)-coated activated charcoal for the adsorption of large lipophilic molecules with exclusion of small hydrophilic molecules (1989) (5)
Artificial Cells: The Beginning of Nanomedicine (2013) (5)
Recent Trends in Biocompatible Materials and Microcapsular Absorbents for Kidney Function Replacement (1973) (5)
Artificial liver support: requirements and approaches. (1983) (5)
Polyhemoglobin-superoxide Dismutase-catalase-carbonic Anhydrase: A Novel Biotechnology-based Blood Substitute that Transports Both Oxygen and Carbon Dioxide and Also Acts as an Antioxidant (2012) (5)
Diacytosis of asialoglycoprotein in isolated hepatocytes is dependent on the structure of ligand and cellular distribution of the receptors. (1989) (4)
Enzymes Immobilized by Microencapsulation Within Spherical Ultrathin Polymeric Membranes (1976) (4)
Urea and ammonium removal based on alkalinization and removal of free ammonia. (1979) (4)
Preparation of carboxymethylchitin-incorporated submicron bilayer-lipid membrane artificial cells (liposomes) encapsulating hemoglobin. (1992) (4)
In-vitro assessment of the removal of phenols by ACAC hemoperfusion. (1979) (4)
Multienzymes and Cofactors Immobilized within Lipid-Polyamide Membrane Microcapsules for Sequential Substrate Conversion (1982) (4)
The role of biotechnology in bioartificial or hybrid artificial cells and organs. (1988) (4)
Kinetic aspects of polyelectrolyte adsorption: adsorption of chitin derivatives onto liposomes as a model system. (1997) (4)
Hemoperfusion: clearance, blood compatibility and safety. (1979) (4)
The importance of standardization of carboxymethylchitin concentration by the dye-binding capacity of alcian blue before adsorption on liposomes. (1996) (4)
Whole complement hemolytic activity (CH50) following infusion of stroma-free and polyhemoglobin solutions in rats. (1990) (4)
Comparison of bilirubin conjugation in encapsulated hepatocytes, hepatocyte homogenate and intact hepatocytes. (1999) (4)
Coated charcoal hemoperfusion for the removal galactose in rats. (1978) (4)
Long‐Term Clinical Assessment of Combined ACAC HemoperfusionUltrafiltration in Uremia (2008) (4)
ARTIFICIAL KIDNEY AND ARTIFICIAL LIVER (1974) (4)
From Hemoglobin Based Oxygen Carrier to Oxygen Therapeutics, Blood Substitutes, Nanomedicine and Artificial Cells (2013) (4)
Immobilized Multienzyme Systems and Coenzyme Requirements: Perspectives in Biomedical Applications (1977) (3)
Safety studies of modified hemoglobin as an oxygen-carrying blood substitute. (1993) (3)
The use of circular dichroism active phospholipid to study lipid transfer between liposomes: effects of cholesterol and melittin on spontaneous lipid transfer (1989) (3)
Selection and microencapsulation of an "NADH-oxidizing" bacterium and its use for NAD regeneration. (1984) (3)
New concepts and theories. (1998) (3)
A preclinical screening test for modified hemoglobin to bridge the gap between animal safety studies and use in human. (1992) (3)
Artificial Cell Including Blood Substitute and Biomicroencapsulation: from Ideas to Applications (1994) (3)
Editorial: Modified Hemoglobin: Endotoxin and Safety Studies (1990) (3)
First Design and Clinical Use in Patients of Surface Modified Sorbent Hemoperfusion Based on Artificial Cells for Poisoning, Kidney Failure, Liver Failure and Immunology (2017) (3)
Conversion of Urea and Ammonia to Amino Acid Using Sequential Enzymatic Reaction with Microencapsulated Multi-Enzyme Systems (1978) (3)
Syntheses and properties of circular dichroism active phospholipids. (1988) (3)
A Nanobiotechnologic Therapeutic that Transports Oxygen and Remove Oxygen Radicals: For Stroke, Hemorrhagic Shock and Related Conditions (2007) (3)
Biomaterials, Artificial Cells, and Artificial Organs: An Editorial (1987) (3)
Conversion of ammonia to glutamate by L-glutamic dehydrogenase, alcohol dehydrogenase and NAD+ immobilized within lipid-polyamide polyethyleneimine microcapsules. (1987) (3)
Removal of Urea in Uremia and Ammonia in Liver Failure with Emphasis on the Use of Artificial Cells for Encapsulation of Genetically Engineered Cells (1999) (3)
The effects of polymer-solvent compositions on the formation of collodion membrane artificial cells. (1980) (3)
The cyanogen bromide fragment I of asialoorosomucoid is transported more efficiently than asialoorosomucoid in rat hepatocytes. (1989) (3)
Safety of red blood cell substitutes as compared to stored donor red blood cells. (2008) (2)
Microencapsulation of enzymes, cells, and genetically engineered microorganisms. (1999) (2)
In vivo effects of intraperitoneally injected L-asparaginase solution and L-asparaginase immobilized within semipermeable nylon microcapsules with emphasis on blood L-asparaginase, 'body' L-asparaginase, and plasma L-asparagine levels. (1974) (2)
Purification and quantitative determination of carboxymethylchitin incorporation into submicron bilayer-lipid membrane artificial cells (liposomes) encapsulating hemoglobin. (1992) (2)
A novel red blood cell substitute based on crosslinked hemoglobin, superoxide dismutase, and catalase / (1997) (2)
Mixing divalent ionic liquids: effects of charge and side-chains. (2021) (2)
Artificial Cells: The Use of Hybrid Systems (2008) (2)
Platelet-surface interaction: effects of dextran 70 on platelet retention in extracorporeal surfaces. (1975) (2)
Mass isolation of highly purified canine islets using an automated method and Histopaque Ficoll gradients. (1993) (2)
Dedication to Dr. Willem Johan Kolff. (2008) (2)
Panel conference. Adsorbent hemoperfusion for blood purification. (1980) (2)
Routine Clinical Applications of Hemodialysis-Hemoperfusion in Chronic Renal Failure: Case Reports (1986) (2)
Blood Substitutes in 2010 [1] (2010) (2)
Effects of temperature on the removal of urea as ammonia by enzymatic conversion and by gas absorption using an oxygenator. (1981) (2)
Direct Differentiation of Human Embryonic Stem Cells to 3D Functional Hepatocyte-like Cells in Alginate Microencapsulation Sphere (2022) (2)
Establishment of the low-level radwaste classification using the dose-to-curie technique at the Lan-Yu Temporary Storage Site, Taiwan (2007) (2)
Artificial Kidney, Artificial Liver, and Detoxifiers Based on Artificial Cells, Immobilized Proteins, and Immobilized Enzymes (1977) (2)
Hemoperfusion: state of the art and future requirements. (1980) (2)
Artificial Cells and Microcapsules: Comparision of Structural and Functional Differences (1974) (2)
Nanotechnology-based Artificial Red Blood Cells (RBCs) (2007) (2)
Chapter II.5.4 – Artificial Cells (2013) (2)
Chapter 38 – Polyhemoglobin–Enzymes as New-Generation Blood Substitutes and Oxygen Therapeutics (2006) (2)
Blood Cell Substitutes (2002) (2)
Study on the variables affecting toxicity of hybrid toxins. The effect of different target cell receptor distribution and toxin binding chain. (1989) (2)
Enzyme Artificial Cells in Substrate-dependent Tumors and Activation of Prodrug (2007) (2)
Microencapsulated Charcoal Hemoperfusion for Galactosemia (1978) (1)
Use of Enzyme Artificial Cells for Genetic Enzyme Defects that Increase Systemic Substrates to Toxic Levels (2007) (1)
Artificial cells with ultrathin lipid-polymer or lipid-protein membranes. (1988) (1)
Use of the Labscale Tangential Flow Diafiltrator to Remove Tetrameric Hemoglobin from Polyhemoglobin, Purify Hemolysate, and Concentrate Polyhemoglobin (2009) (1)
Artificial cells and charcoal hemoperfusion. (1978) (1)
ARTIFICIAL CELLS CONTAINING DETOXICANTS * (2002) (1)
Medical Applications of Artificial Cells in Transfusion, Phenylketonuria, Essential Amino Acid Production, and Liver Support a (1988) (1)
An urgent need to include blood substitute as a priority area in any national policies on blood supply. (1997) (1)
APPENDIX I 1957 Report on “ Method for Preparing Artificial Hemoglobin Corpuscles ” (2008) (1)
Artificial Cells Containing Hepatocytes and/or Stem Cells in Regenerative Medicine (2007) (1)
Artificial Cells for Blood Substitutes, Enzyme Therapy, Cell Therapy and Drug Delivery (2005) (1)
Effects of air and fluid flow rates on removing different concentrations of urea and ammonia from fluid by gas absorption in a capillary hemodialyzer. (1980) (1)
CHAPTER 42 – RED BLOOD CELL SUBSTITUTES (2000) (1)
PAST, PRESENT AND FUTURE PERSPECTIVES ON THE 40TH ANNIVERSARY OF HEMOGLOBIN BASED RED BLOOD CELL SUBSTITUTES (2007) (1)
Artificial Cells for Artificial Liver Support (1992) (1)
Standard of efficacy for red blood cell substitutes. (1994) (1)
Perspectives on the Future of Artificial Cells as Suggested by Past Research (2007) (1)
50th Anniversary of Artificial Cells (2007) (1)
The role of artificial cells in the fight against COVID-19: deliver vaccine, hemoperfusion removes toxic cytokines, nanobiotherapeutics lower free radicals and pCO2 and replenish blood supply (2022) (1)
A polymer–lipid membrane artificial cell nanocarrier containing enzyme–oxygen biotherapeutic inhibits the growth of B16F10 melanoma in 3D culture and in a mouse model (2021) (1)
Long Term Safety and Immunological Effects of a Nanobiotherapeutic, Bovine Poly-[hemoglobin-catalase-superoxide dismutase-carbonic anhydrase], After Four Weekly 5% Blood Volume Toploading Followed by a Challenge of 30% Exchange Transfusion (2021) (1)
ARTIFICIAL CELLS FOR ARTIFICIAL ORGANS * (2002) (1)
Is there a role for first generation blood substitutes in the resuscitation of hemorrhagic shock? (1998) (1)
Artificial kidney, artificial liver, and artificial cells : [proceedings of the McGill Artificial Organs Research Unit international symposium, McGill University, April 20, 1977] (1978) (1)
A Novel Nanobiotherapeutical Poly-[hemoglobin-superoxide dismutase-catalase-carbonic anhydrase] with No Cardiac Toxicity for the Resuscitation of a 90-minute Sustained Severe Hemorrhagic Shock Rat Model with Two-third Blood Volume Loss (2021) (1)
Rationale for the use of the acac microcapsule artificial kidney for the treatment of patients with chronic renal failure. (1975) (1)
News on Artificial Cells, Blood Substitutes & Immobilization Biotechnology (1994) (0)
Artificial cells. Preparation. 1972 [classical article]. (2002) (0)
A Nanobiotechnologic Therapeutic that Transports Oxygen and Removes Oxygen Radicals (2021) (0)
Memorials for Editorial Board Members: Debakey, Kolff, and Winslow (2009) (0)
Biological activity of artificial cells. 1972 [classical article]. (2002) (0)
Artificial cells. Biophysical properties. 1972 [classical article]. (2002) (0)
Roger Yonchien Tsien, 錢永健 2008 Nobel Laureate in Chemistry 2004 Wolf Laureate in Medicine (2019) (0)
Chapter 45 – Nanodimension Biodegradable Polymeric Membrane Artificial Red Blood Cells (2006) (0)
Artificial cells perfused by body fluids. 1972 [classical article]. (2002) (0)
Chapter 49 – Red Blood Cell Substitutes (2014) (0)
7.5 ARTIFICIAL RED BLOOD CELL SUBSTITUTES (2004) (0)
Long term safety and immunological effects of a nanobiotherapeutic , bovine poly-[hemoglobin-catalase-superoxide dismutase-carbonic anhydrase], after four weekly 5% blood volume top-loading followed by a challenge of 30% exchange (2021) (0)
Book Review:Uses of Enzymes and Immobilized Enzymes. Francis X. Hasselberger (1979) (0)
Microencapsulation: Artificial Cells (2015) (0)
Immobilization of proteins and enzymes onto functionalized polypropylene surfaces by a gaseous plasma modification technique (1989) (0)
The History, Development and Promise of Artificial Cells: Microdialyzers and Nanodialyzers with Bioreactive Properties (2012) (0)
Artificial cells. General discussions and perspectives. 1972 [classical article]. (2002) (0)
Peptidoglycan is an important pathogenic factor of the inflammatory response in sepsis * (2004) (0)
Methods for Bioencapsulation of Enzymes and Cells (2005) (0)
Artificial Cells for Cell Encapsulation (2007) (0)
Immune Safety Evaluation of Polymerized Porcine Hemoglobin (pPolyHb) — Potential Red Blood Cell Substitutes (2021) (0)
EXPERIMENTAL ENZYME THERAPY * (2002) (0)
Oxygen Carriers Based on Nanobiotechnology (2007) (0)
Nanobiotechnological basis of an oxygen carrier with enhanced carbonic anhydrase for CO2 transport and enhanced catalase and superoxide dismutase for antioxidant function (2023) (0)
Microencapsulation: An introduction (1984) (0)
Red blood cell substitutes. 1972 [classical article]. (2002) (0)
Plasmonic wormholes (2011) (0)
THE COENCAPSULATED HEPATOCYTES WITH BONE MARROW CELLS HEPATOCYTES VIABILITY AND FUNCTION EXTENDED BOTH IN VITRO AND IN VIVO (2004) (0)
ARTIFICIAL CELLS PERFUSED BY BODY FLUIDS * (2002) (0)
Conversion of ammonia or urea into L-leucine, L-valine, and L-isoleucine using artificial cells containing an immobilized multienzyme system and dextran-NAD+. Glucose dehydrogenase for co-factor recycling. (1988) (0)
Artificial cells containing detoxicants. 1972 [classical article]. (2002) (0)
Red Blood Cell Substitutes: Past, Present, and Future (2005) (0)
Hybrid Artificial Organs (2008) (0)
Lipid-nylon membrane artificial cells containing multienzyme systems, cofactors and substrates for the sequential conversion of ammonia and urea into glutamate. (1981) (0)
Nanobiotherapeutics as Preservation Fluids for Organs and Cells (2021) (0)
Summary and abstracts of the International Symposium on Hemoperfusion: Kidney and Liver Supports and Detoxification. August 25-26, 1979, Haifa, Israel. (2008) (0)
Artificial cell-encapsulated enzymes and adsorbents in congenital metabolic disorders (1982) (0)
A novel approach to restore function of stroke or trauma related paralyzed limbs (2017) (0)
Nanotechnology-based Complete Artificial Red Blood Cells (2021) (0)
Artificial cells for artificial organs. 1972 [classical article]. (2002) (0)
Development of polarizable chloroform potential and its applications to chloroform-water liquid-liquid interface (1996) (0)
Effects of Different Routes of In Vivo Administration of Microencapsulated Enzymes (1974) (0)
THE ROLE OF BIOTECHNOLOGY IN ARTIFICIAL ORGANS IN THE 21st CENTURY (1995) (0)
International Meeting on Hemoperfusion, Bologna, March 16, 1981. (1982) (0)
Artificial cells in 1977. (1978) (0)
Unlimited Potential of Nanobiotechnology-based Blood Substitutes, Artificial Cells and Nanobiotherapeutics (2021) (0)
GENERAL DISCUSSIONS AND PERSPECTIVES * (2002) (0)
Dual Antioxidant and Pro-Oxidation Effects of Ascorbic Acid on Bovine Hemoglobin (2021) (0)
Artificial Organs: Thoughts & Progress:Plasma β-Endorphin Levels In Chronic Schizophrenic Patients and Normal Controls (2008) (0)
Effect of size and conformation of the ligand on asialoglycoprotein receptor-mediated ligand internalization and degradation in rat hepatocytes (1987) (0)
Preparation and in vitro characteristics of a blood substitute based on pyridoxylated polyhemoglobin (1984) (0)
BIOLOGICAL ACTIVITY OF ARTIFICIAL CELLS (2002) (0)
Human hemoglobin anaerobically reacted with divinyl sulfone: a source for oxygen carriers. (1994) (0)
12 – Artificial cells in medicine: with emphasis on blood substitutes (2007) (0)
PREPARATION * (1996) (0)
Molecular dynamics simulation of clusters, liquid, and interface of carbon tetrachloride (1995) (0)
The passing of a pioneer in perfluorocarbon blood substitutes. (1997) (0)
Recent Advances in Artificial Cells With Emphasis on Biotechnological and Medical Approaches Based on Microencapsulation (2020) (0)
Experimental enzyme therapy. 1972 [classical article]. (2002) (0)
Chapter Fifty – Red Blood Cell Substitutes (2007) (0)
Artificial cells. General consideration. 1972 [classical article]. (2002) (0)
ISAO-ASAIO Workshop: Blood Substitutes: Present and Future (2004) (0)
Isolated heart preservation for 24 hours: is O2 important? (1988) (0)
Soluble Nanobiotherapeutics with Enhancements of all Three Major Red Blood Cell Functions (2021) (0)
Plasma beta-endorphin levels in chronic schizophrenic patients normal controls. (1979) (0)
Geotechnical Characterisation of Krishna Godavari Basin Sediments, Offshore Eastern India (2020) (0)
Artificial Cells Containing Stem Cells for Liver Failure. (2010) (0)
Hemoperfusion in Poisoning, Kidney Failure, Liver Failure, and Immunology (2007) (0)
Gordon Research Conference on Drug Carriers in Biology and Medicine, 12-16 July 1982, Plymouth, New Hampshire. (1983) (0)
Comments on Dr. Estep's “letter to the editor”: (2011) (0)
n Why Do We Need Blood Substitutes ? (0)
Bioreactor for the conversion of ammonia into L-valine based on microcapsules each containing multienzyme system with cofactor-dextran recycling (1992) (0)

This paper list is powered by the following services:

Other Resources About Thomas Chang

en.wikipedia.org

What Schools Are Affiliated With Thomas Chang?

Thomas Chang is affiliated with the following schools:

Image Attributions

Image Source for Thomas Chang